Held by 2 specialist biotech funds
**Signal Note: Eventide's TYL Entry Signals Confidence in Healthcare IT Consolidation Play** This $24.2M initiation in Tyler Technologies (a healthcare software/ERP platform provider) by values-focused Eventide likely reflects conviction in secular tailwinds around healthcare digitalization and interoperability mandates, rather than a biotech-specific catalyst. The position aligns with Eventide's broader healthcare infrastructure thesis, positioning TYL to benefit from regulatory push toward data standardization across provider networks—relevant as biotech/pharma increasingly rely on integrated health systems for real-world evidence generation and market access.